Member Info for Basser1

Very interesting Bobbler. It is clear that new generation anti virals can play a part but as the article states “ but with increasing resistance to anti virals it is important to have alternative therapies perhaps in combination. I do not think that our immune systems would ever become resistant to TYK2 inhibitors like SDC 1801 as it controls immune over reaction. . Happy to be corrected on this view.

Moneywise - if as you say you believe the science is very special why are you worrying about next week’s share price? Surely if you are confident about the quality of the science and the genius of John Reader you should be prepared to sit patiently and wait for news to arrive? The LTHs here are not bothered about next weeks share price because it’s irrelevant to their longer term strategy. Or have you got an ulterior motive here?

I’m not bothered by any new covid treatments as we will need a range of approaches in our armoury. I do think we have an edge in that the top scientific papers and the WHO have pinpointed TYK2 as an approach warranting further trialling. Oh and also we have a tablet and we think- it has low toxicity issues. That to me puts us at the even money favourite.

HL showing nearly 260 Million share traded so like yesterday around £80 million not shown.

To me that 7.20 buy is making a statement. Could have bought at much lower price. Warning shot for wombles!!

And we’ve trounced their Market Cap!

Dot!

If the red door happens it is temporary. The quality of the science is permanent.

It’ s good news that there are other therapeutics being developed just like there has been for vaccines. It’s a Pandemic so there is plenty of room for competition. I have every confidence that John Reader will deliver a quality product just like he did for our Checkpoint inhibitor SRRA. Personally I would expect it to be near the top of the therapeutic pile of choice.

There were a number of sec 4 forms published after close today. Krone can you take a look as my Virgin edit internet is f..... after yesterday’s outage. Cheers

So this paper was published in Jan 2019. Sareum new the potential opportunities. for virus inhibition then. Maybe they could have acted quicker when the pandemic emerged, although I understand why they were focusing on autoimmune at that time. I take from this that potentially this can be a treatment in the future for a range of different viruses. Is so it’s massive.

Thoth- perhaps it was because they had a recommendation from Link China Pharma solutions based in Cambridge who have a good relationship with Sareum. Seem to recall some tweets from them that indicted that they though that SDC1801 was very good, albeit in Autoimmune?

3.70 my guess. Too much profit taking. Fine by me as happy to see gradual rise before news arrives.It’s two years this months since Sierra presented SRRA737 data at ASCO and then announced they were shelving it. Comment below from Tim in the resulting Sareum RNS. Dr Tim Mitchell, CEO of Sareum Holdings plc, added: "The clinical results presented with SRA737 at ASCO and the identification of a route to market in a cancer indication with high unmet need, together with preclinical work highlighting it in combination with other leading therapeutic modalities, clearly demonstrate the value that could be created through the further development of SRA737. We are confident that these qualities of SRA737, based on the excellent work done to date, will be recognised and that Sierra will be successful in securing the strategic options it is seeking."It’s a tragedy for for us but more importantly for patients, some of whom had unmet needs. Two years of further development through trials wasted.

Thanks Stoney. An intriguing post. Tim said there was regular meetings with Govt officials who monitored and reported back progress. So it seems likely that the progress to date will have kick in forward planning of trials and the manufacturing of the dosage etc. To have to finish a 6 months study and then submit an application for scrutiny does not fit in with the urgency needed in a Pandemic.

That’s right Warthog. The only way is up but not in a straight line. More importantly the future funding for SDC1801 has been sorted. Covid grant application is nailed on.So we can sit back and enjoy the next four weeks. And the sun is shining too! What more could we want. Happy days!

Hi Utah - the Edison report highlighted the depth of competition in autoimmune. Can’t understand your conclusion. SD1801 just has to be as good as or better than the competition to be successful. Are you saying it is not?

And just for balance - if SD1801 fails in Covid we will be back probably to under 1p and face a wait to see how the autoimmune trials progress and how SRA737 makes an impact on cancer combo trials.

Ahfam - I do not think we will get anywhere near a pound on pure speculation or anticipation. But If SD1801 saves from 5 out of every ten lives or more without any side effects then a pound would seem more realistic.

WIP. I am sure that many of us on here, especially long term holders, will feel the same. Only I would say ‘will’ rather than ‘might’.

Thanks Leggster. The multiple opportunities demonstrated by SD1801 in Autoimmune and SRA737 in a range of Cancers is clearly a massive opportunity for a big pharma with resources to fully exploit the potential. Exciting times!